| Drug Name |
Didanosine |
| Drug ID |
BADD_D00661 |
| Description |
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite. |
| Indications and Usage |
For use, in combination with other antiretroviral agents, in the treatment of HIV-1 infection in adults. |
| Marketing Status |
approved |
| ATC Code |
J05AF02 |
| DrugBank ID |
DB00900
|
| KEGG ID |
D00296
|
| MeSH ID |
D016049
|
| PubChem ID |
135398739
|
| TTD Drug ID |
D06FDR
|
| NDC Product Code |
65015-794; 65862-400; 65862-322; 68554-0012 |
| UNII |
K3GDH6OH08
|
| Synonyms |
Didanosine | Dideoxyinosine | 2',3'-Dideoxyinosine | 2',3' Dideoxyinosine | ddI (Antiviral) | Videx | NSC-612049 | NSC 612049 | NSC612049 |
